This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of
oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks. Secondary
endpoints to evaluate clinical parameters for psoriasis during the 6 week treatment period
and a 4-week follow up will provide an opportunity to perform a first assessment of oral
MP1032's clinical efficacy in the treatment of moderate to severe psoriasis.
The study population will consist of 44 enrolled (40 completed) patients with moderate to
severe chronic plaque psoriasis. Patients must be able to provide written consent and meet
all the inclusion criteria and none of the exclusion criteria.